Umoja Biopharma Inc. and Nanjing Iaso Biotherapeutics Co. Ltd. have entered into a research agreement to evaluate Umoja's ICIL (induced cytotoxic innate lymphocytes) platform with Iaso's best-in-class chimeric antigen receptors (CARs).
Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).
In relapsed/refractory acute myeloid leukemia (AML), an indication that still needs adequate standard-of-care therapy, Actinium Pharmaceuticals Inc.’s topline pivotal phase III data shone brightly with radiotherapy lead candidate Iomab-B.
Maxinovel Pharmaceuticals Inc. raised ¥100 million (US$13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.
Maxinovel Pharmaceuticals Inc. raised ¥100 million ($13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.
It’s been a rough year at Macrogenics Inc., but times may be changing. Having terminated a phase II study due to fatalities, dropped 15% of its workforce and closed research and manufacturing sites in the past year, the company has taken the helping hand of Gilead Sciences Inc. The pair have agreed to develop the bispecific MGD-024, which has a CD3 component for minimizing cytokine release syndrome, as an oncology candidate along with two additional bispecific research programs, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Researchers from Abl Bio Inc. recently presented preclinical data for the novel asymmetrical CLL1/CD3 bispecific antibody ABL-602, being developed for the treatment of acute myeloid leukemia (AML).
